#METABOLOMICS WORKBENCH hormel101_20180712_130954 DATATRACK_ID:1442 STUDY_ID:ST001005 ANALYSIS_ID:AN001647 PROJECT_ID:PR000680
VERSION             	1
CREATED_ON             	July 12, 2018, 5:24 pm
#PROJECT
PR:PROJECT_TITLE                 	Mayo Pilot and Feasibility: Metabolomics of Muscle Wasting in Cancer Cachexia
PR:PROJECT_SUMMARY               	"Cachexia is a debilitating syndrome that results in severe, involuntary weight
PR:PROJECT_SUMMARY               	loss due to the depletion of skeletal muscle mass. This syndrome occurs in a
PR:PROJECT_SUMMARY               	majority of cancers and contributes to approximately one third of all cancer
PR:PROJECT_SUMMARY               	deaths. Currently, no effective therapy exists to combat this malignant
PR:PROJECT_SUMMARY               	disorder, and disappointing results from recent Phase III clinical trials
PR:PROJECT_SUMMARY               	indicate that a cachexia treatment is not likely to appear soon. Thus, it is
PR:PROJECT_SUMMARY               	clear that greater knowledge of the mechanisms driving muscle wasting in
PR:PROJECT_SUMMARY               	cachexia is needed in order to identify new therapeutic targets and stimulate
PR:PROJECT_SUMMARY               	new clinical trials. Our approach to gaining this knowledge has been to work
PR:PROJECT_SUMMARY               	with muscle biopsies from pancreatic cancer patients, since this population is
PR:PROJECT_SUMMARY               	highly prone to cachexia. We have also been expanding our studies beyond the
PR:PROJECT_SUMMARY               	classical mouse models of cancer cachexia in hopes of finding a new model that
PR:PROJECT_SUMMARY               	better recapitulates the human disease. We recently undertook RNA-Seq analysis
PR:PROJECT_SUMMARY               	comparing muscle biopsies from pancreatic cancer patients with and without
PR:PROJECT_SUMMARY               	cachexia, which has been exciting since this type of analysis has not yet been
PR:PROJECT_SUMMARY               	performed in patient samples. Preliminary results revealed that cachectic muscle
PR:PROJECT_SUMMARY               	was associated with alterations in metabolism. These data provide the rationale
PR:PROJECT_SUMMARY               	for performing metabolomics to ascertain whether specific metabolic pathways or
PR:PROJECT_SUMMARY               	metabolites can be identified as potential drivers of muscle wasting in cachexia
PR:PROJECT_SUMMARY               	or be used as biomarker of cachexia, which the field desperately needs. An
PR:PROJECT_SUMMARY               	additional need is a well-validated animal model of cancer cachexia that
PR:PROJECT_SUMMARY               	accurately reflects the human condition, which can be used to test mechanisms
PR:PROJECT_SUMMARY               	and pre-clinical compounds. We propose to perform these studies under the Mayo
PR:PROJECT_SUMMARY               	Clinic Metabolomics Resource Core Pilot and Feasibility Grant program to: 1)
PR:PROJECT_SUMMARY               	Identify metabolic alterations and biomarkers of pancreatic cancer-induced
PR:PROJECT_SUMMARY               	muscle wasting; and 2) Identify a suitable mouse model that recapitulates the
PR:PROJECT_SUMMARY               	metabolic imbalance of muscles from pancreatic cancer cachexia patients. By
PR:PROJECT_SUMMARY               	performing these studies, we will accelerate our understanding of the underlying
PR:PROJECT_SUMMARY               	causes of muscle wasting, which should translate to improving the current
PR:PROJECT_SUMMARY               	pipeline of anticachexia therapies. "
PR:INSTITUTE                     	Mayo Clinic
PR:LAST_NAME                     	Guttridge
PR:FIRST_NAME                    	Denis
PR:ADDRESS                       	520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
PR:EMAIL                         	denis.guttridge@osumc.edu
PR:PHONE                         	614-688-3137
#STUDY
ST:STUDY_TITLE                   	Amino Acid Concentrations in Muscle Tissue of Muscle Wasting in Cancer Cachexia
ST:STUDY_TITLE                   	(part I)
ST:STUDY_SUMMARY                 	Amino Acid Concentrations of Muscle Wasting in Cancer Cachexia. Muscle samples
ST:STUDY_SUMMARY                 	from 10 control patients, 10 weight stable pancreatic cancer patients, and 10
ST:STUDY_SUMMARY                 	pancreatic cancer patients with significant weight loss. Samples are divided
ST:STUDY_SUMMARY                 	evenly between males and females.
ST:INSTITUTE                     	Mayo Clinic
ST:LAST_NAME                     	Guttridge
ST:FIRST_NAME                    	Denis
ST:ADDRESS                       	520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
ST:EMAIL                         	denis.guttridge@osumc.edu
ST:PHONE                         	614-688-3137
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	ms6644-1	Grouping:Weight Losing	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=128
SUBJECT_SAMPLE_FACTORS           	-	ms6644-2	Grouping:Weight Losing	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=81
SUBJECT_SAMPLE_FACTORS           	-	ms6644-3	Grouping:Weight Stable	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=91
SUBJECT_SAMPLE_FACTORS           	-	ms6644-4	Grouping:Control	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=185
SUBJECT_SAMPLE_FACTORS           	-	ms6644-5	Grouping:Control	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=265
SUBJECT_SAMPLE_FACTORS           	-	ms6644-6	Grouping:Control	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=308
SUBJECT_SAMPLE_FACTORS           	-	ms6644-7	Grouping:Weight Stable	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=105
SUBJECT_SAMPLE_FACTORS           	-	ms6644-8	Grouping:Weight Stable	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=67
SUBJECT_SAMPLE_FACTORS           	-	ms6644-9	Grouping:Control	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=196
SUBJECT_SAMPLE_FACTORS           	-	ms6644-10	Grouping:Control	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=164
SUBJECT_SAMPLE_FACTORS           	-	ms6644-11	Grouping:Weight Stable	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=264
SUBJECT_SAMPLE_FACTORS           	-	ms6644-12	Grouping:Control	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=111
SUBJECT_SAMPLE_FACTORS           	-	ms6644-13	Grouping:Weight Stable	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=136
SUBJECT_SAMPLE_FACTORS           	-	ms6644-14	Grouping:Weight Losing	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=126
SUBJECT_SAMPLE_FACTORS           	-	ms6644-15	Grouping:Weight Losing	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=112
SUBJECT_SAMPLE_FACTORS           	-	ms6644-16	Grouping:Weight Stable	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=203
SUBJECT_SAMPLE_FACTORS           	-	ms6644-17	Grouping:Control	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=163
SUBJECT_SAMPLE_FACTORS           	-	ms6644-18	Grouping:Weight Losing	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=111
SUBJECT_SAMPLE_FACTORS           	-	ms6644-19	Grouping:Weight Losing	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=139
SUBJECT_SAMPLE_FACTORS           	-	ms6644-20	Grouping:Control	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=283
SUBJECT_SAMPLE_FACTORS           	-	ms6644-21	Grouping:Weight Losing	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=93
SUBJECT_SAMPLE_FACTORS           	-	ms6644-22	Grouping:Control	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=209
SUBJECT_SAMPLE_FACTORS           	-	ms6644-23	Grouping:Weight Stable	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=206
SUBJECT_SAMPLE_FACTORS           	-	ms6644-24	Grouping:Weight Losing	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=72
SUBJECT_SAMPLE_FACTORS           	-	ms6644-25	Grouping:Control	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=315
SUBJECT_SAMPLE_FACTORS           	-	ms6644-26	Grouping:Weight Stable	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=113
SUBJECT_SAMPLE_FACTORS           	-	ms6644-27	Grouping:Weight Losing	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=215
SUBJECT_SAMPLE_FACTORS           	-	ms6644-28	Grouping:Weight Losing	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=116
SUBJECT_SAMPLE_FACTORS           	-	ms6644-29	Grouping:Weight Stable	Gender=Female; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=135
SUBJECT_SAMPLE_FACTORS           	-	ms6644-30	Grouping:Weight Stable	Gender=Male; Sample type=Muscle Tissue; Species=Human; tissue mg/vial=5; protein ug/vial=248
#COLLECTION
CO:COLLECTION_SUMMARY            	Tissue and blood donated from Cancer Cachexia Program at Ohio State University
CO:SAMPLE_TYPE                   	Muscle
#TREATMENT
TR:TREATMENT_SUMMARY             	"Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer,
TR:TREATMENT_SUMMARY             	with the most notable symptom being unintentional weight loss. Cachectic
TR:TREATMENT_SUMMARY             	patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss
TR:TREATMENT_SUMMARY             	and its associated weakness contributing to the morbidity and mortality of these
TR:TREATMENT_SUMMARY             	patients. Despite three decades of research into mechanisms driving muscle
TR:TREATMENT_SUMMARY             	wasting due to cancer, to date, an approved pharmacological therapy to prevent
TR:TREATMENT_SUMMARY             	or treat cancer cachexia is still lacking. Our laboratory focuses on cancer
TR:TREATMENT_SUMMARY             	cachexia in patients with pancreatic cancer, as up to 85% of these patients
TR:TREATMENT_SUMMARY             	experience weight loss. Cachexia often occurs early in the progression of
TR:TREATMENT_SUMMARY             	pancreatic cancer, making clear that cachexia in these patients is not simply a
TR:TREATMENT_SUMMARY             	result of end-stage disease. Further, with perhaps more than ¼ of all
TR:TREATMENT_SUMMARY             	pancreatic cancer deaths resulting from muscle weakness as opposed to tumor
TR:TREATMENT_SUMMARY             	burden, cachexia also significantly contributes to mortality due to pancreatic
TR:TREATMENT_SUMMARY             	cancer. Because little progress has been made in improving treatment outcomes,
TR:TREATMENT_SUMMARY             	addressing cancer-induced muscle wasting is perhaps the best strategy to prolong
TR:TREATMENT_SUMMARY             	pancreatic cancer patient survival and increase patient quality of life. In an
TR:TREATMENT_SUMMARY             	effort to better understand the mechanisms driving pancreatic cancer-induced
TR:TREATMENT_SUMMARY             	muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a
TR:TREATMENT_SUMMARY             	Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing
TR:TREATMENT_SUMMARY             	attempted resection for pancreatic cancer or other abdominal surgeries have
TR:TREATMENT_SUMMARY             	donated muscle and blood to our bank. A unique aspect of our tissue bank is our
TR:TREATMENT_SUMMARY             	focus on patients eligible for resection. In contrast to other studies using
TR:TREATMENT_SUMMARY             	patients with late-stage disease, our patients are not end-stage, as they are
TR:TREATMENT_SUMMARY             	considered healthy enough to undergo a major operation. "
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	amino acids concentrations using muscle tissue
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	Waters Acquity BEH C18 (150 x 2.1mm, 1.7um)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	Thermo Quantum Ultra
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	nmoles/vial
MS_METABOLITE_DATA_START
Samples	ms6644-1	ms6644-2	ms6644-3	ms6644-4	ms6644-5	ms6644-6	ms6644-7	ms6644-8	ms6644-9	ms6644-10	ms6644-11	ms6644-12	ms6644-13	ms6644-14	ms6644-15	ms6644-16	ms6644-17	ms6644-18	ms6644-19	ms6644-20	ms6644-21	ms6644-22	ms6644-23	ms6644-24	ms6644-25	ms6644-26	ms6644-27	ms6644-28	ms6644-29	ms6644-30
Factors	Grouping:Weight Losing	Grouping:Weight Losing	Grouping:Weight Stable	Grouping:Control	Grouping:Control	Grouping:Control	Grouping:Weight Stable	Grouping:Weight Stable	Grouping:Control	Grouping:Control	Grouping:Weight Stable	Grouping:Control	Grouping:Weight Stable	Grouping:Weight Losing	Grouping:Weight Losing	Grouping:Weight Stable	Grouping:Control	Grouping:Weight Losing	Grouping:Weight Losing	Grouping:Control	Grouping:Weight Losing	Grouping:Control	Grouping:Weight Stable	Grouping:Weight Losing	Grouping:Control	Grouping:Weight Stable	Grouping:Weight Losing	Grouping:Weight Losing	Grouping:Weight Stable	Grouping:Weight Stable
Histidine	0.54	0.79	0.94	1.58	1.22	1.17	0.84	0.16	1.44	0.57	1.69	0.98	1.01	1.16	1.64	1.26	0.90	1.05	0.25	1.43	0.26	1.58	1.09	0.50	1.28	0.44	0.56	0.41	0.60	1.42
Hydroxyproline	0.06	0.09	0.09	0.14	0.11	0.11	0.07	0.01	0.27	0.13	0.19	0.10	0.13	0.04	0.08	0.08	0.10	0.12	0.07	0.15	0.03	0.17	0.15	0.10	0.08	0.13	0.06	0.08	0.03	0.14
1-Methylhistidine	0.000	0.075	0.000	0.026	0.000	0.000	0.000	0.000	0.040	0.058	0.000	0.000	0.000	0.042	0.037	0.000	0.000	0.000	0.000	0.000	0.030	0.000	0.079	0.026	0.000	0.047	0.000	0.035	0.000	0.062
3-Methylhistidine	0.013	0.035	0.000	0.044	0.029	0.031	0.019	0.000	0.079	0.024	0.014	0.029	0.016	0.022	0.016	0.013	0.043	0.000	0.000	0.033	0.011	0.037	0.020	0.000	0.041	0.033	0.008	0.035	0.000	0.019
Asparagine	0.44	0.57	0.44	0.69	0.67	0.99	0.59	0.17	0.53	0.55	0.80	0.39	0.48	0.64	0.51	0.40	0.49	0.44	0.41	0.91	0.25	0.66	0.55	0.52	0.69	0.43	0.64	0.42	0.19	0.87
Phosphoethanolamine	0.24	0.26	0.31	0.37	0.46	0.27	0.22	0.12	0.34	0.25	0.46	0.43	0.33	0.31	0.33	0.30	0.22	0.29	0.21	0.48	0.07	0.67	0.41	0.27	0.48	0.19	0.44	0.24	0.22	0.42
Arginine	0.98	1.75	2.62	1.77	2.00	1.70	1.94	0.37	2.46	2.08	1.69	1.12	2.19	1.82	1.63	1.05	1.45	0.84	0.99	2.77	1.08	1.27	1.28	1.20	1.49	1.12	1.42	1.19	0.56	1.25
Carnosine	12.50	5.24	2.76	10.87	5.44	13.30	6.02	1.32	11.23	16.22	18.47	8.23	5.55	12.46	6.48	7.26	13.83	16.35	6.47	12.02	4.95	8.34	19.73	14.78	16.56	5.76	18.58	7.16	2.41	12.03
Taurine	10.84	6.41	10.89	15.22	10.13	11.82	7.30	2.81	17.30	6.21	8.37	10.99	8.24	5.72	11.37	6.57	17.41	9.49	8.83	12.89	4.02	9.19	11.43	5.22	12.94	9.06	11.66	10.69	1.90	11.47
Anserine	0.31	0.10	0.04	0.15	0.11	0.23	0.08	0.03	0.23	0.29	0.21	0.15	0.07	0.29	0.19	0.10	0.15	0.37	0.11	0.15	0.09	0.12	0.21	0.19	0.23	0.11	0.16	0.08	0.04	0.13
Serine	1.20	1.20	0.79	1.31	1.39	1.46	0.78	0.30	0.60	1.40	1.21	0.86	0.59	0.92	1.03	0.64	0.86	0.91	0.67	1.07	0.67	1.18	0.96	0.81	0.96	0.67	1.15	0.66	0.31	1.49
Glutamine	17.48	27.22	29.87	21.18	42.98	38.08	11.96	3.93	21.25	18.50	24.80	10.44	16.94	24.45	14.86	11.89	28.44	13.41	14.11	27.05	11.11	21.81	22.37	19.45	25.90	13.78	17.55	21.79	5.95	32.11
Ethanolamine	0.04	0.03	0.03	0.06	0.07	0.06	0.04	0.01	0.06	0.04	0.06	0.04	0.04	0.03	0.04	0.06	0.04	0.04	0.02	0.06	0.02	0.06	0.05	0.05	0.06	0.02	0.05	0.04	0.02	0.08
Glycine	3.01	3.17	2.47	4.42	4.69	4.86	1.90	0.66	2.56	3.15	3.07	2.38	2.35	2.98	2.55	1.59	3.89	2.87	1.47	4.68	1.93	5.42	3.06	2.15	2.48	2.15	3.00	2.40	0.87	3.86
Aspartic Acid	0.54	0.96	0.91	0.37	0.65	0.76	0.32	0.15	0.05	0.33	1.07	0.37	0.59	0.78	0.23	0.17	0.31	0.24	0.11	0.64	0.14	0.26	0.64	0.42	0.63	0.41	0.56	0.17	0.07	0.28
Sarcosine	0.01	0.00	0.01	0.02	0.01	0.01	0.01	0.00	0.02	0.01	0.02	0.01	0.01	0.00	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.02	0.01	0.01	0.01	0.00	0.02	0.00	0.00	0.01
Citrulline	0.21	0.18	0.23	0.09	0.24	0.48	0.12	0.03	0.37	0.52	0.25	0.09	0.13	0.42	0.06	0.17	0.13	0.09	0.02	0.28	0.12	0.10	0.23	0.21	0.37	0.06	0.18	0.08	0.07	0.28
Glutamic Acid	2.37	2.23	4.65	3.38	2.76	4.02	1.83	0.60	3.47	1.76	3.48	1.91	3.43	1.48	2.16	1.83	2.54	0.77	2.53	1.83	0.68	5.07	1.94	1.28	3.29	1.99	2.03	2.13	0.55	1.80
beta-Alanine	0.31	0.15	0.15	0.80	0.19	0.32	0.27	0.09	0.38	0.06	0.64	0.42	0.36	0.34	0.97	0.68	0.26	0.43	0.15	0.37	0.02	0.50	0.38	0.18	0.26	0.26	0.30	0.19	0.47	0.18
Threonine	0.70	0.76	0.92	1.04	1.28	1.57	0.74	0.26	1.73	1.23	1.75	0.81	0.91	1.39	0.63	0.75	0.94	0.74	0.60	1.44	0.53	0.99	1.00	1.07	1.15	0.49	0.99	0.84	0.32	1.37
Alanine	3.72	5.95	3.26	6.68	3.78	6.63	4.94	1.46	6.32	6.67	9.76	4.20	6.64	4.91	6.29	5.02	5.52	4.78	3.53	9.33	3.16	7.89	8.46	5.69	8.20	3.14	7.34	4.76	2.14	8.29
gamma-Amino-N-butyric-acid	0.006	0.005	0.005	0.007	0.007	0.019	0.010	0.001	0.013	0.007	0.010	0.005	0.010	0.007	0.007	0.009	0.008	0.013	0.003	0.011	0.002	0.025	0.010	0.003	0.008	0.013	0.004	0.013	0.001	0.018
alpha-Aminoadipic-acid	0.076	0.028	0.223	0.092	0.201	0.081	0.132	0.003	0.118	0.050	0.140	0.046	0.135	0.126	0.094	0.046	0.093	0.021	0.090	0.091	0.074	0.079	0.049	0.073	0.120	0.061	0.081	0.074	0.013	0.123
beta-Aminoisobutyric-acid	0.007	0.015	0.001	0.006	0.017	0.031	0.013	0.002	0.011	0.009	0.004	0.002	0.004	0.004	0.010	0.020	0.008	0.002	0.001	0.017	0.006	0.009	0.009	0.002	0.010	0.017	0.007	0.003	0.001	0.005
Proline	0.72	1.49	2.57	1.26	2.17	1.82	1.04	0.34	2.28	2.41	2.36	1.40	1.57	1.21	1.23	1.34	1.02	1.49	0.90	1.90	0.70	2.51	1.83	1.42	1.65	0.69	1.18	0.88	0.51	1.53
Hydroxylysine 1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Hydroxylysine 2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
alpha-Amino-N-butyric-acid	0.14	0.11	0.03	0.18	0.33	0.20	0.09	0.01	0.21	0.15	0.24	0.11	0.06	0.23	0.24	0.19	0.10	0.18	0.11	0.23	0.16	0.14	0.10	0.11	0.20	0.08	0.29	0.15	0.04	0.19
Ornithine	0.24	0.68	1.53	0.64	0.79	0.37	0.45	0.11	0.72	0.85	0.44	0.38	0.69	0.61	0.53	0.39	0.37	0.19	0.25	0.56	0.32	0.42	0.35	0.39	0.41	0.48	0.32	0.27	0.17	0.51
Cystathionine 1	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Cystathionine 2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Lysine	1.98	3.78	2.97	3.54	3.06	3.48	2.64	0.47	3.76	2.08	2.95	1.83	2.89	2.75	3.34	2.00	2.37	1.40	1.65	3.53	1.65	2.70	2.05	2.62	2.58	1.54	2.80	1.85	0.99	2.49
Cystine	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.01	0.01	0.02	0.02	0.01	0.01	0.00	0.01	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Tyrosine	0.24	0.17	0.21	0.28	0.28	0.37	0.23	0.15	0.31	0.26	0.40	0.34	0.22	0.26	0.26	0.29	0.19	0.27	0.13	0.37	0.10	0.30	0.33	0.36	0.29	0.14	0.25	0.16	0.15	0.33
Methionine	0.11	0.08	0.10	0.15	0.17	0.18	0.12	0.07	0.16	0.17	0.20	0.18	0.10	0.14	0.13	0.16	0.12	0.13	0.07	0.23	0.05	0.18	0.20	0.18	0.16	0.06	0.15	0.09	0.08	0.17
Valine	0.40	0.35	0.45	0.77	0.77	0.51	0.45	0.18	0.69	0.62	0.76	0.63	0.37	0.48	0.52	0.71	0.49	0.52	0.32	0.70	0.23	0.72	0.77	0.65	0.89	0.25	0.58	0.48	0.28	0.79
Isoleucine	0.19	0.17	0.17	0.27	0.36	0.19	0.19	0.07	0.28	0.28	0.30	0.24	0.15	0.19	0.23	0.24	0.19	0.18	0.14	0.29	0.10	0.25	0.31	0.28	0.26	0.10	0.25	0.17	0.12	0.29
allo-Isoleucine	0.00	0.01	0.00	0.01	0.01	0.00	0.00	0.00	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.00	0.00	0.01
Homocystine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leucine	0.37	0.27	0.33	0.56	0.69	0.44	0.36	0.17	0.51	0.42	0.56	0.55	0.31	0.37	0.44	0.51	0.39	0.41	0.26	0.70	0.18	0.58	0.59	0.55	0.62	0.20	0.47	0.37	0.23	0.62
Phenylalanine	0.22	0.15	0.19	0.26	0.27	0.31	0.24	0.13	0.28	0.20	0.34	0.34	0.21	0.21	0.23	0.28	0.21	0.22	0.14	0.38	0.09	0.35	0.27	0.28	0.31	0.12	0.25	0.16	0.15	0.32
Tryptophan	0.06	0.05	0.04	0.07	0.08	0.07	0.07	0.02	0.06	0.07	0.10	0.08	0.06	0.06	0.06	0.08	0.05	0.05	0.04	0.10	0.02	0.07	0.09	0.09	0.08	0.03	0.06	0.04	0.05	0.09
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
Histidine
Hydroxyproline
1-Methylhistidine
3-Methylhistidine
Asparagine
Phosphoethanolamine
Arginine
Carnosine
Taurine
Anserine
Serine
Glutamine
Ethanolamine
Glycine
Aspartic Acid
Sarcosine
Citrulline
Glutamic Acid
beta-Alanine
Threonine
Alanine
gamma-Amino-N-butyric-acid
alpha-Aminoadipic-acid
beta-Aminoisobutyric-acid
Proline
Hydroxylysine 1
Hydroxylysine 2
alpha-Amino-N-butyric-acid
Ornithine
Cystathionine 1
Cystathionine 2
Lysine
Cystine
Tyrosine
Methionine
Valine
Isoleucine
allo-Isoleucine
Homocystine
Leucine
Phenylalanine
Tryptophan
METABOLITES_END
#END